Method of Inhibition of Respiratory Depression Using Positive Allosteric AMPA Receptor Modulators

Abstract

The invention is directed to a method for alleviating respiratory depression in a subject as a result of disease of pharmacological agents such as opiates, opioids or barbiturates. The invention also discloses pharmaceutical compositions for use with the method, the composition containing in combination, an analgesic, anaesthetic, or a sedative and a positive allosteric AMPA receptor modulator in an amount sufficient to reduce or inhibit respiratory depression caused by the analgesic, anaesthetic, or sedative.

What is claimed is: 
     
         1 . A method for reducing or inhibiting respiratory depression in a subject, comprising administering to the subject having respiratory depression a therapeutically effective amount of a positive allosteric AMPA receptor modulator sufficient to reduce or inhibit the respiratory depression wherein the respiratory depression results from the subject having a medical condition selected from the group consisting of: central sleep apnea, stroke-induced central sleep apnea, obstructive sleep apnea, sleep apnea resulting from Parkinson's disease, congenital hypoventilation syndrome, sudden infant death syndrome, Retts syndrome, Cheney-Stokes respiration, Ondines Curse, spinal muscular atrophy, amyotrophic lateral sclerosis, Prader-Willi's syndrome, spinal cord injury, traumatic brain injury, and drowning. 
     
     
         2 . The method of  claim 1  wherein the medical condition is central sleep apnea. 
     
     
         3 . The method of  claim 1  wherein the medical condition is stroke-induced central sleep apnea. 
     
     
         4 . The method of  claim 1  wherein the medical condition is obstructive sleep apnea. 
     
     
         5 . The method of  claim 1  wherein the medical condition is sleep apnea resulting from Parkinson's disease. 
     
     
         6 . The method of  claim 1 , wherein the positive allosteric AMPA receptor modulator is a benzofurazan compound. 
     
     
         7 . The method of  claim 1 , wherein the positive allosteric AMPA receptor modulator is selected from the group consisting of: CX546, CX614, 1-(benzofurazan-5-ylcarbonyl)-4,4-difluoropiperidine, and 4-(benzofurazan-5-ylcarbonyl)morpholine. 
     
     
         8 . The method of  claim 1 , wherein the subject is a mammal. 
     
     
         9 . The method of  claim 8 , wherein the mammal is a human.